| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/24/2008 | US20080096922 N-{[cis-1-(3-methoxyphenyl)-4-(piperidin-4-ylamino)-cyclohexyl]methyl}sulfamide diHCL; tert-butyl [({[cis-4-[(biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl}amino)sulfonyl]carbamate; for potentiating expression of low density lipoprotein recepotr; arteriosclerosis; hyperlipidemia |
| 04/24/2008 | US20080096921 Farnesoid x receptor agonists |
| 04/24/2008 | US20080096916 Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants |
| 04/24/2008 | US20080096915 Compositions for the treatment of metabolic disorders |
| 04/24/2008 | US20080096913 peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance; 3-[5-Methoxy-1-(3-methoxy-benzyl)-1H-indol-3-yl]-propionic acid |
| 04/24/2008 | US20080096908 Nitrate derivatives of atorvastatin with improved pharmacological activity and enhanced tolerability; coronary syndromes, neurodegenerative disorders, and for reducing cholesterol levels; antiinflammatory, antithrombotic and antiplatelet activity; fluvastatin 4-(nitrooxy)butyl ester |
| 04/24/2008 | US20080096906 good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; (3-Chloro-phenyl)-(1H-imidazol-2-ylmethyl)-methyl-amine from 3-chloro-N-methylaniline and imidazole-2-carboxyaldehyde and reduction of the carbonyl to methylene |
| 04/24/2008 | US20080096904 Compositions and methods for treatment and prevention of insulin resistance |
| 04/24/2008 | US20080096895 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors |
| 04/24/2008 | US20080096890 Highly Selective Norepinephrine Reuptake Inhibitors and Methods of Using the Same |
| 04/24/2008 | US20080096887 Benzene, Pyridine, and Pyridazine Derivatives |
| 04/24/2008 | US20080096880 Use of imidazo[1,2,4]triazinones which are inhibitors of cGMP-metabolizing phosphodiesterases (PDE I, II and V) to treat cardiovascular disorders, urogenital disorders, prostate hyperplasia, ocular disorders such as glaucoma, optic neuropathy, diabetic gastroparesis, dementia |
| 04/24/2008 | US20080096877 Glucokinase activators; prophylaxis or treatment of diabetes, obesity; sulfonamide or sulfonate-functional thiazole or thiadiazole-substituted indoles; N,N-dimethyl-2-{4-[(2-{7-[methyl(2-thienylsulfonyl)amino]-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]piperazin-1-yl}acetamide for example |
| 04/24/2008 | US20080096874 Oxadiazole Derivative as Dgat Inhibitors |
| 04/24/2008 | US20080096873 New compounds |
| 04/24/2008 | US20080096869 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 04/24/2008 | US20080096862 Lactam compounds and pharmaceutical use thereof |
| 04/24/2008 | US20080096842 Preventive/Remedy for Obesity |
| 04/24/2008 | US20080096841 Using analogs of Lipid A such as Eritoran to treat or prevent mucositis, allograft/graft rejection, arteriosclerosis, atherosclerosis, hepatitis, asthma, and inflammatory bowel disease |
| 04/24/2008 | US20080096825 Preparation and Use of Phlorizin Compositions |
| 04/24/2008 | US20080096811 Selective vpac2 receptor peptide agonists |
| 04/24/2008 | US20080096802 administering peroxisome proliferator-activated receptor agonists (PPAR) and sodium glucose co-transporters (SGLTs) inhibitors for the treatment of diabetes and Syndrome X |
| 04/24/2008 | US20080096800 Rapid mucosal gel or film insulin compositions |
| 04/24/2008 | US20080096799 Compounds for and methods of treating insulin resistance and inflammation |
| 04/24/2008 | US20080096250 Expression vector comprising nucleotide sequences coding inflammatory response polypeptide for use in treatment and prevention of inflammation |
| 04/24/2008 | US20080095867 extracting and reacting the hydroxycitric acid with IA and IIA group metals of periodic table, isolating the metal salt and drying and optionally mixing anthocyanins to obtain the synergistic compositions; beverages and powdered beverage premixes |
| 04/24/2008 | US20080095851 Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability |
| 04/24/2008 | US20080095838 Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof |
| 04/24/2008 | US20080095782 Using secreted glycoprotein (Lipocalin-2) for treatment of obesity and as evaluative tool in detection of glucose tolerance, insulin resistance and Type 2 diabetes in mammals |
| 04/24/2008 | US20080095774 Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| 04/24/2008 | US20080095766 Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity |
| 04/24/2008 | US20080095762 Glycoprotein compositions |
| 04/24/2008 | US20080095741 Using reduced lipoic acid as tool in treatment of pancreatic disorders; antidiabetic agents |
| 04/24/2008 | DE202007004776U1 Neue pharmazeutische Zusammensetzungen für die Lipolyse New pharmaceutical compositions for lipolysis |
| 04/24/2008 | CA2666375A1 3-aminoimidazo[1,2-a]pyridine derivatives having an sglt1- and sglt2- inhibiting action for the treatment of type 1 and type 2 diabetes |
| 04/24/2008 | CA2664849A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 04/23/2008 | EP1914310A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/23/2008 | EP1914305A1 GSK3 polypeptides |
| 04/23/2008 | EP1914237A2 Phosphonate ester antiviral compounds |
| 04/23/2008 | EP1914232A1 N-dihydroxyalkyl-substituted 2-oxoimidazole derivative |
| 04/23/2008 | EP1914229A1 Novel cercosporamide derivative |
| 04/23/2008 | EP1913945A2 Composition based on a thiazolidinedione and metformin and its use |
| 04/23/2008 | EP1912993A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912992A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912991A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912990A1 Hydrochlorides and hydrates of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their preparation and their use as medicaments |
| 04/23/2008 | EP1912986A1 Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| 04/23/2008 | EP1912978A2 Ppar / agonists and processes of preparing |
| 04/23/2008 | EP1912968A1 Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| 04/23/2008 | EP1912964A2 Dihydroxyanthraquinones and their use |
| 04/23/2008 | EP1912960A1 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound and use thereof as a hypolipidaemic |
| 04/23/2008 | EP1912952A1 Process for preparing amorphous rosuvastatin calcium free of impurities |
| 04/23/2008 | EP1912946A1 Pyridine derivatives as dipeptedyl peptidase inhibitors |
| 04/23/2008 | EP1912938A2 Salts of vildagliptin |
| 04/23/2008 | EP1912937A1 Novel substituted azetidinones |
| 04/23/2008 | EP1912706A2 Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors |
| 04/23/2008 | EP1912669A2 Sustained release preparations of pro-insulin c-peptide |
| 04/23/2008 | EP1912656A2 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
| 04/23/2008 | EP1912650A1 Use of flibanserin in the treatment of obesity |
| 04/23/2008 | EP1912645A2 Therapeutic agent for diabetes |
| 04/23/2008 | EP1912642A2 Synthesis and crystalline forms of npy5 antagonist |
| 04/23/2008 | EP1912638A2 Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids |
| 04/23/2008 | EP1912635A2 Use of chk2 kinase inhibitors for cancer treatment |
| 04/23/2008 | EP1912632A2 Compositions for treating or preventing obesity and insulin resistance disorders |
| 04/23/2008 | EP1474145B1 Quinoline derivatives as npy antagonists |
| 04/23/2008 | EP1420643B1 Enhancement of transfection of dna into the liver |
| 04/23/2008 | EP1372673B1 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body |
| 04/23/2008 | EP1333834B1 Antiinflammation agents |
| 04/23/2008 | EP1305312B1 Tartrate salts of thiazolidinedione derivative |
| 04/23/2008 | EP1303483B1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 04/23/2008 | EP1272516B1 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 04/23/2008 | EP1211305B1 Fat compositions |
| 04/23/2008 | EP0763116B2 Recombinant viruses, preparation and use thereof in gene therapy |
| 04/23/2008 | CN101166751A Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1 |
| 04/23/2008 | CN101166742A Novel lactam compound |
| 04/23/2008 | CN101166730A Cinnoline compounds and their use as liver X receptor modilators |
| 04/23/2008 | CN101166725A Pyridylacetic acid compound |
| 04/23/2008 | CN101166720A Activator for peroxisome proliferator activating receptor delta |
| 04/23/2008 | CN101166706A Hydroquinone long-chain derivative and/or phenoxy long-chain derivative, and pharmaceutical preparation comprising the same |
| 04/23/2008 | CN101166545A GLP-1 pegylated compounds |
| 04/23/2008 | CN101166529A Benzotriazole derivatives as cannabinoid receptor antagonists |
| 04/23/2008 | CN101165053A N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| 04/23/2008 | CN101165052A N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| 04/23/2008 | CN101165036A Ether compounds, compositions, and uses thereof |
| 04/23/2008 | CN101164618A A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| 04/23/2008 | CN101164606A Traditional Chinese medicine historic preparation for treating diabetes and compication abnormality on blood lipid |
| 04/23/2008 | CN101164566A Peony leaves total glycoside extract, its preparation method and application |
| 04/23/2008 | CN101164564A Medicine for reducing blood sugar and lowering blood fat or health-care food composition |
| 04/23/2008 | CN100383141C Pyrazolo [4,3-d] pyrimidine derivatives |
| 04/23/2008 | CN100383132C Azoles as malonyl-COA decarboxylase inhibitors useful as metabolic modulators |
| 04/23/2008 | CN100383130C Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome. |
| 04/23/2008 | CN100383129C Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/23/2008 | CN100383124C Quinoline derivatives as NPY antagonists |
| 04/23/2008 | CN100382807C Natural medicine composition for preventing and treating metabolic syndrome |
| 04/22/2008 | US7361783 Agonists for human PPAR alpha isoform; exhibit lipid-lowering effect, inhibitory effect on the arteriosclerosis, antiobesity effect, blood glucose-lowering effect; 2-{[3-(N-{[4-(3,5-bistrifluoromethylphenoxy)phenyl]methyl}carbamoyl)-4-methoxyphenyl]methyl}butyric acid |
| 04/22/2008 | US7361758 crystal of a non-solvate of (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-[4-(4-carboxyphenyloxy)phenylmethyl]-1,4,9-triazaspiro[5.5]undecane hydrochloride; chemokine antagonist |
| 04/22/2008 | US7361744 Oligosaccharide derivative |
| 04/22/2008 | US7361687 Antagonists of the B2 receptor of bradykinin; analgesics; hyperalgesia and major algesia; cancer; nontoxic; industrial scale; 5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide |
| 04/22/2008 | US7361684 Screening of compounds for treatment of atherosclerosis and heart attack |
| 04/22/2008 | US7361678 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents |